Global Regenerative Medicine Partnering Deal Trends, Players, Financials and Forecasts Report 2019

DUBLIN, Dec. 5, 2019 /PRNewswire/ -- The "Global Regenerative Medicine Partnering 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Partnering 2014-2019: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1000 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.

Key benefits

• In-depth understanding of Regenerative Medicine deal trends since 2014
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Regenerative Medicine agreements with numerous real life case studies
• Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
• Identify most active Regenerative Medicine dealmakers since 2014
• Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Regenerative Medicine Partnering Terms and Agreements includes:

• Trends in Regenerative Medicine dealmaking in the biopharma industry since 2014
• Analysis of Regenerative Medicine deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life Regenerative Medicine deals
• Access to Regenerative Medicine contract documents
• Leading Regenerative Medicine deals by value since 2014
• Most active Regenerative Medicine dealmakers since 2014

Available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Regenerative Medicine dealmaking
2.1. Introduction
2.2. Regenerative Medicine partnering over the years
2.3. Most active Regenerative Medicine dealmakers
2.4. Regenerative Medicine partnering by deal type
2.5. Regenerative Medicine partnering by therapy area
2.6. Deal terms for Regenerative Medicine partnering
2.6.1 Regenerative Medicine partnering headline values
2.6.2 Regenerative Medicine deal upfront payments7
2.6.3 Regenerative Medicine deal milestone payments
2.6.4 Regenerative Medicine royalty rates

Chapter 3 - Leading Regenerative Medicine deals
3.1. Introduction
3.2. Top Regenerative Medicine deals by value

Chapter 4 - Most active Regenerative Medicine dealmakers
4.1. Introduction
4.2. Most active Regenerative Medicine dealmakers
4.3. Most active Regenerative Medicine partnering company profiles

Chapter 5 - Regenerative Medicine contracts dealmaking directory
5.1. Introduction
5.2. Regenerative Medicine contracts dealmaking directory

Chapter 6 - Regenerative Medicine dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Regenerative Medicine deals by company A-Z

Appendix 2 - Regenerative Medicine deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Regenerative Medicine deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 - Regenerative Medicine deals by therapy area

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/9q4rpy

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com